ZOLADEX LA DEPOT INJECTION 10.8 mgsyringe

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

GOSERELIN

Available from:

ASTRAZENECA SINGAPORE PTE LTD

ATC code:

L02AE03

Dosage:

10.8 mg/syringe

Pharmaceutical form:

INJECTION

Composition:

GOSERELIN 10.8 mg/syringe

Administration route:

SUBCUTANEOUS

Prescription type:

Prescription Only

Manufactured by:

ASTRAZENECA UK LTD

Authorization status:

ACTIVE

Authorization date:

1998-06-04

Patient Information leaflet

ZOLADEX LA
goserelin 10.8mg
GOSERELIN 10.8 MG
CONTAINS ONE DEPOT IN A PREFILLED SAFESYSTEM
TM SYRINGE WITH A PROTECTIVE SLEEVE.
USE IMMEDIATELY AFTER OPENING POUCH.
USE ONLY IF POUCH IS UNDAMAGED.
‘Zoladex’ LA contains goserelin acetate equivalent to 10.8 mg
peptide base in a long acting
sustained release depot.
Also contains Lactide/Glycolide copolymer.
For subcutaneous injection.
To be administered as directed by the prescriber.
_FOR ADMINISTRATION EVERY 12 WEEKS. _
See reverse for directions for use.
Do no store above 25°C.
Keep all medicines away from children.
This pouch contains a small white desiccant capsule which is to be
discarded after opening
the pouch.
ASTRAZENECA UK LIMITED
Macclesfield, Cheshire
United Kingdom
Made in United Kingdom
Zoladex is a trade mark of the AstraZeneca group of companies.
© AstraZeneca 2003
To open tear at arrows.
ZOLADEX LA 10.8 MG
goserelin
The following information is intended for medical or healthcare
professionals only:
ZOLADEX IS ADMINISTERED BY SUBCUTANEOUS INJECTION - READ AND
UNDERSTAND ALL THE INSTRUCTIONS
FULLY PRIOR TO ADMINISTRATION
1.
Put the patient in a comfortable position with the upper part of the
body slightly raised.
Prepare the injection site according to the local policy and
procedure.
NOTE: Caution should be taken while injecting Zoladex into the
anterior abdominal wall due to the
proximity of underlying inferior epigastric artery and its branches;
very thin patients may be at higher
risk of vascular injury.
2.
Examine the foil pouch and syringe for damage. Remove the syringe from
the opened foil pouch
and hold the syringe at a slight angle to the light.
Check that at least part of the Zoladex depot is visible
(FIGURE 1).
FIGURE 1.
3.
Grasp the plastic safety tab and pull away from the syringe and
discard
(FIGURE 2).
Remove
needle cover. UNLIKE LIQUID INJECTIONS, THERE IS NO NEED TO REMOVE AIR BUBBLES AS
ATTEMPTS TO DO SO
MAY DISPLACE THE ZOLADEX DEPOT.
FIGURE 2.
4.
Holding the syringe around the protective sleeve, using an aseptic
technique, pin

Summary of Product characteristics

ZOLADEX
® LA
goserelin 10.8mg
GOSERELIN 10.8 MG
CONTAINS ONE DEPOT IN A PREFILLED SAFESYSTEM
® SYRINGE WITH A PROTECTIVE SLEEVE.
USE IMMEDIATELY AFTER OPENING POUCH.
USE ONLY IF POUCH IS UNDAMAGED.
‘Zoladex’ LA contains goserelin acetate equivalent to 10.8 mg
peptide base in a long acting
sustained release depot.
Also contains Lactide/Glycolide copolymer.
For subcutaneous injection.
To be administered as directed by the prescriber.
_FOR ADMINISTRATION EVERY 12 WEEKS. _
See reverse for directions for use.
Do not store above 25°C.
Keep out of the reach of children.
This pouch contains a small white desiccant capsule which is to be
discarded after opening
the pouch.
ASTRAZENECA UK LIMITED
Macclesfield, Cheshire SK10 2NA
United Kingdom
Made in United Kingdom
ZOLADEX SAFESYSTEM is a trademark of the AstraZeneca group of
companies.
© AstraZeneca 2021
To open tear at arrows.
ZOLADEX
® LA 10.8 MG
goserelin
The following information is intended for medical or healthcare
professionals only:
ZOLADEX IS ADMINISTERED BY SUBCUTANEOUS INJECTION - READ AND
UNDERSTAND ALL THE INSTRUCTIONS
FULLY PRIOR TO ADMINISTRATION
1.
Put the patient in a comfortable position with the upper part of the
body slightly raised.
Prepare the injection site according to the local policy and
procedure.
NOTE: Caution should be taken while injecting Zoladex into the
anterior abdominal wall due to the
proximity of underlying inferior epigastric artery and its branches;
very thin patients may be at higher
risk of vascular injury.
2.
Examine the foil pouch and syringe for damage. Remove the syringe from
the opened foil pouch
and hold the syringe at a slight angle to the light.
Check that at least part of the Zoladex depot is visible
(FIGURE 1).
FIGURE 1.
3.
Grasp the plastic safety tab and pull away from the syringe and
discard
(FIGURE 2).
Remove
needle cover. UNLIKE LIQUID INJECTIONS, THERE IS NO NEED TO REMOVE AIR BUBBLES AS
ATTEMPTS TO DO SO
MAY DISPLACE THE ZOLADEX DEPOT.
FIGURE 2.
4.
Holding the syringe around the protective sleeve, using an